Garuda - Garba Rujukan Digital

p-Index From 2020 - 2025

5.848

P-Index

This Author published in this journals

All Journal Farmasains : Jurnal Farmasi dan Ilmu Kesehatan Jurnal Kedokteran Brawijaya Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice) Media Farmasi : Jurnal Ilmu Farmasi (Journal Of Pharmaceutical Science) Jurnal Kesehatan Folia Medica Indonesiana Jurnal Farmasi Klinik Indonesia Pharmacon MPI (Media Pharmaceutica Indonesiana) Pharmascience JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Pharmasipha PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia) JFIOnline Pharmaceutical Journal of Indonesia JFM (Jurnal Farmasi Malahayati) JURNAL FARMASIMED (JFM) Majalah Farmasetika Jurnal Ilmiah Farmasi Farmasyifa Budapest International Research in Exact Sciences (BirEx Journal) Hubungan Tingkat Pengetahuan Petugas Pengelola Obat dengan Tingkat Ketersediaan Obat Di Puskesmas Kota Malang Jurnal Farmasi dan Sains Indonesia (JFSI) Indonesian Journal of Pharmaceutical Education Journal of Global Pharma Technology Journal of Tropical Pharmacy and Chemistry Jurnal Sains dan Kesehatan Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice)

Didik Hasmono

Department Of Clinical Pharmacy, Faculty Of Pharmacy, Universitas Airlangga

Author-ID : 278212

Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemistry Civil Engineering, Building, Construction & Architecture Education Environmental Science Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Neuroscience Nursing Physics Public Health Transportation Other

Published : 72 Documents Claim Missing Document

Claim Missing Document

Articles

2 3 4 5 6

STUDI PENGGUNAAN OBAT NEUROPROTEKTAN PADA PASIEN STROKE ISKEMIK (Penelitian Di Rumah Sakit Umum Dr. Saiful Anwar Malang) Dini Setiya Praja; Didik Hasmono; Nailis Syifa
PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia) Jurnal Pharmacy, Vol. 10 No. 02 Desember 2013
Publisher : Pharmacy Faculty, Universitas Muhammadiyah Purwokerto

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30595/pji.v10i2.796

ABSTRAK Stroke adalah sebuah penyakit pada sistem saraf yang disebabkan penyumbatan atau terjadinya luka pada pembuluh darah di otak. Stroke merupakan penyebab kelumpuhan nomor satu di dunia, pembunuh nomor dua di dunia dan merupakan peringkat ketiga penyebab kematian di Amerika Serikat. Stroke iskemik adalah stroke yang paling sering terjadi dengan angka kejadian 88%. Tujuan pengobatan stroke akut adalah menurukan terjadinya kerusakan saraf lebih lanjut dan menurunkan kematian dan kelumpuhan jangka panjang. Neuroprotectan adalah salah satu terapi yang dapat menurunkan kerusakan sel yang mengakibatkan gangguan pembuluh darah untuk mensuplai oksigen. Penelitian bertujuan untuk menentukan pola penggunaan neuroprotectan pada pasien dengan stroke iskemik serta memeriksa hubungan terapi neuroprotectan terkait dosis, rute pemberian, frekuensi pemberian, lama dan waktu pemberian yang dikaitkan dengan data klinik di rumah sakit Dr. Saiful Anwar Malang. Penelitian ini menggunakan pengamatan retrospektif dengan consecutive sampling method pada pasien stroke iskemik dari bulan Oktober 2012 sampai Desember 2012. Pada penelitian ini menunjukkan bahwa 95 pasien (93,14%) menerima citicoline, 2 pasien (4,90%) menerima piracetam, dan 5 pasien (4,90%) menerima kombinasi citicoline dan piracetam. Neuroprotectan yang digunakan secara i.v. dan oral dengan (2x1g)/i.v. citicoline kemudian (2x1g)/p.o sebanyak 27 pasien (26,47%). Penggunaan dosis neuroprotectan, rute pemberian, interval pemberian, dan lama pemberian yang diberikan pada pasien stroke iksemik di rumah sakit Dr. Saiful Anwar sudah sesuai berdasarkan beberapa guidelines yang ada. Kata kunci: neuroprotektan, rumah sakit, stroke iskemik. ABSTRACT Stroke is a neurological disease caused by a blockage or rupture of blood vessels in the brain. Stroke is the number one cause of disability in the world, the second leading killer worldwide and the third leading cause of death in the United States. Ischemic stroke is the most common type of stroke that occurs 88%. The goal of acute stroke treatment are to reduce the ongoing neurologic injury and decrease mortality and long-term disability. Neuroprotectan is one of therapy that intended to reduce the occurrence of cell damage due to impaired blood flow to supply oxygen.The study aims to determine patterns of neuroprotectan utilization in patient with ischemic stroke and to examine the relationship neuroprotectan therapy related to the dose, route of administration, frequency of administration, duration and timing of administration associated with clinical data at the Hospital of Dr. Saiful Anwar Malang. The study is a retrospective observational with consecutive sampling method in ischemic stroke patients from october to december 2012. This study showed there were 95 patients (93.14%) received citicoline, 2 patients (4.90%) received piracetam, and 5 patients (4.90%) received combination of citicoline-piracetam. Neuroprotectan used by i.v and oral administration dominated with (2x1g)/iv citicoline then (2x1g)/p.o as 27 patients (26,47%). The use of neuroprotectan dose, route of administration, interval of administration, and duration of administration that given in ischemic stroke patients in inpatient Dr. Saiful Anwar was appropriate according to some existing guidelines. Key words: neuroprotectan, inpatients, ischemic stroke.

Studi Penggunaan Obat Anti Tuberkulosis (OAT) Tahap Lanjutan pada Pasien Baru BTA Positif Tista Ayu Fortuna; Hidajah Rachmawati; Didik Hasmono; Hidayah Karuniawati
Pharmacon: Jurnal Farmasi Indonesia Vol 19, No 1 (2022)
Publisher : Universitas Muhammadiyah Surakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.23917/pharmacon.v19i1.17907

Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. Tuberculosis will cause pain and death if not treated properly. OAT (Antituberculosis Drugs) is a treatment for tuberculosis patients. OAT has different dosage regimens and types of drugs. Treatment of TB patients consists of two phases (intensive and continuation phases). The continuation phase was at to kill dormant bacteria to prevent recurrence in patients. The purpose of this study was to determine and evaluate the pattern of using OAT in patients newly diagnosed rwith smear-positive at the continuation phase. This study is an observational descriptive study with results showing that the pattern of using OAT-KDT in patients was 89% and OAT-Separated was 11%. The pattern of using the OAT-KDT dose was 1x3 2KDT tablets. Another combination of antibiotics given to the patient is cotrimoxazole at a dose of 1x960mg. The side effect of OAT is an increase in serum transaminase and nausea each with a percentage of 23%. Based on the research, it can be concluded that the pattern of using OAT in Tuberculosis patients has followed the guidelines for the management of Tuberculosis treatment.

STUDY OF EFFECTIVENESS AND SIDE EFFECTS OF FAVIPIRAVIR THERAPY ON MILD AND MODERATE COVID-19 PATIENTS Didik Hasmono; Alfa Frista Arta; Ismawati; Ruddy Hartono; Mohammad Subhan
Jurnal Kesehatan Vol 15 No 2 (2022): JURNAL KESEHATAN
Publisher : Universitas Islam Negeri Alauddin Makassar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24252/kesehatan.v15i2.29380

Introduction: Corona Virus Disease-2019 (COVID-19) is divided into five degrees that are asymptomatic, mild, moderate, severe and critical. Recently, Favipiravir known as off-label antivirals for COVID-19 that inhibits RNA-dependent RNA polymerase (RdRp) and is administered orally 2x1600 mg as loading dose and 2x600 mg as a maintenance dose. Methods: This observational retrospective study aims to determine effectiveness (PCR/Rapid Ag, temperature, respiratory rate, oxygen saturation, and chest X-ray) and side effects (digestive, uric acid, liver, blood, glucose, and lipids profile) of Favipiravir in mild and moderate COVID-19; which inclusion criteria were Favipiravir (5-10 days); a group of antibacterials: Azithromycin (therapy A), Levofloxacin (therapy B), and combination (therapy C); vitamins, minerals, symptomatic and comorbid therapy; and Fondaparinux used in moderate degree then described quantitatively. Results: This study obtained 47 HMR dominated by males (55%), aged 19-30 years (36%), cough symptoms (72,3%), and no comorbid status (70.2%). Favipiravir (6-7 days) is effective for mild and moderate degree in all effectiveness parameters with average length in mild degree was 6-12 days and moderate degree was 8-13 days. Possible interaction with Paracetamol was found. Most side effects were diarrhea and no significant side effects were found on liver profile (AST and ALT), glucose profile, and blood profile (leukocytes and erythrocytes). Conclusions: This result suggests that increasing collaboration of pharmacists with other healthcare in monitoring the use of Favipiravir related to interactions, uric acid, and lipid profiles, also effects in patients under 18 years, men, and elderly is important.

Isoprinosine along with Favipiravir or Oseltamivir in Patients with Moderate Covid-19 at RSD Dr. Soebandi Jember Chrysnanda Maryska; Didik Hasmono; Sofiati Diah Baisuni; Ayunda Nur Hidayatiningsih; Arina Dery Puspitasari; Retna Dwi Puspitarini; Budi Suprapti
JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 9 No. 3 (2022): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jfiki.v9i32022.209-219

Background: Isoprinosine is an immunomodulator that is now being used to treat Covid-19 patients. Objectives: To evaluate Isoprinosine with Favipiravir or Oseltamivir in moderate Covid-19. Methods: In a retrospective observational analysis, in-hospital moderate Covid-19 patients treated between June 2020 and June 2021 were included. Results: Inclusion criteria for 364 patients were met, with 135 receiving Favipiravir-Isoprinosine (Group 1) and 229 receiving Oseltamivir-Isoprinosine (Group 2). In group 1, the majority of patients (58.50%) were female (35.60%), had no comorbidities (71.60%), were discharged with a positive PCR (74.80%), did not require a breathing apparatus (99.26%), had leukocyte levels between 4,5-11,0 (82.22%), lymphocyte levels between 25-33 (34.07%), and were discharged with no ground-glass opacity (34.07%) (54.10%), LOS was 9-13 days (50.37%), while the mortality rate was 0.70%. In group 2, the majority of patients were male (54.10%), with the highest age range being 42-56 years (35.80%), without comorbidities (69.0%), discharged with a positive PCR (72.50 %), and without the need for a breathing apparatus (99.13%), with leukocyte levels ranging from 4.5 – 11.0 (81.22 %), with lymphocyte levels ranging from 25.0 – 33.0 (26.20 %), and were discharged with no ground-glass opacity (49.34 %), LOS was 9 - 13 days (34.06 %), and the mortality rate was 0.87%.Conclusion: In this trial, it was determined that combining isoprinosine with antivirals favipiravir or Oseltamivir could produce significant clinical improvement.

Studi Penggunaan Carboplatin untuk Penderita Kanker Payudara di RUMKITAL Dr. Ramelan Surabaya Alfin Giovani; Didik Hasmono; Siti Surdijati; Joko Semedi
Jurnal Farmasi Sains dan Terapan Vol 7, No 1 (2020): Februari
Publisher : Jurnal Farmasi Sains dan Terapan

Cancer is an abnormal growth of new cells that grow beyond normal limits. Cancer can metastasize by attacking parts of the body and spread to other organs. The prevalence of cancer Indonesian’s people in 2013 is estimated at 347,792. Breast cancer is the most common cancer in women with a percentage of 23%. Breast cancer is the second most common cancer with death after cervical cancer. Breast cancer is divided according to histologic subtype to Ductal Carcinoma in Situ (DCIS) and Lobular Carcinoma in Situ (LCIS). Carboplatin is a platinum analog cancer drug that belongs to the class of antineoplastic agents. Carboplatin doses used in AUC 6 (i.v) breast cancer chemotherapy for 1 cycle with 21 days to 6 cycle times. This research was conducted observasional with descriptive research design and retrospective data retrieval. The purpose of this study was to know the profile of carboplatin as an anti-cancer drug that is expected to provide safe treatment. This research was conducted at Dr. RUMKITAL Ramelan Surabaya with the number of inclusion of 30 patients in the period January 1, 2017 - December 31, 2017. From the results of this study obtained the use of single carboplatin as much as 7% and a combination of 93%. Patients with chemotherapy administered without surgery and surgery were 73% and 27%, respectively. Toxicity of nausea and vomiting happen as much as 42% and pain as much as 19%.

The Use of Diuretics on Hepatic Cirrhosis Patient with Ascites Didik Hasmono
Journal of Global Pharma Technology Volume 11 Issue 6.
Publisher : Journal of Global Pharma Technology

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (391.694 KB)

Background: Hepatic cirrhosis with ascites complication increases the mortality up to 50% in a matter of years. Diuretics are a class of drugs that are often used as choices. The pattern of diuretics use of hepatic cirrhosis patient with ascites in the hospital needs to be studied further because if the use is not appropriate, it will potentially lead to drug related problems that affect patient management. Aim: to examine the pattern of diuretics use of hepatic cirrhosis patient with ascites which undergoing treatment in the hospital inpatient unit. Method: a descriptive and retrospective study using medical records. Criteria for inclusion of the sample were (1) Hepatic cirrhosis patient with ascites complication (2) Age> 20 years (3) Receive diuretic therapy (4) Complete medical record. The exclusion criteria were patient who was hospitalized for less than 3 days. Study samples were recorded on the data collection sheet. Sampling with time limited sampling method. Result: The total number of patients who met the inclusion criteria was 45 patients. The diuretics which most used was furosemide, both in single doses and in combination with Spironolactone. The hepatic cirrhosis patient with ascites in this study not only received diuretic therapy, but patient also received other drugs that used to prevent and overcome complication. In drug interaction, the potential use of Spironolactone with Potassium (KCl or KSR) preparation increases the risk of hyperkalemia. Conclusion: Most of the diuretic therapies obtained by hepatic cirrhosis patient with those who were hospitalized which have been in accordance with the available guidelines.Keywords: As cites, Drug Related Problems, Diuretics, Hepatic Cirrhosis.

Antibiotic Use Evaluation in ICU/HCU of Muhammadiyah University General Hospital Malang using DDD and Gyssens Methods Hidajah Rachmawati; Muktamiroh Muktamiroh; Didik Hasmono; Atika Putri Kusumaningtyas; Sendi Lia Yunita; Lilik Yusetyani
Jurnal Kedokteran Brawijaya Vol. 32 No. 3 (2023)
Publisher : Fakultas Kedokteran Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.jkb.2023.032.03.7

Infection is a condition caused by the propagation of harmful microorganisms with or without clinical symptoms. Improper use of antibiotics can lead to antibiotic resistance. The Ministry of Health of the Republic of Indonesia recommended a quantitative evaluation of the use of antibiotics using the Defined Daily Dose (DDD) method and a qualitative evaluation using the Gyssens method. This study evaluated antibiotics usage using DDD and Gyssens methods in ICU/HCU of the Muhammadiyah University General Hospital Malang. Employing retrospective observational method, data were collected from patient medical records hospitalized during January-December 2020. Results of the DDD quantitative analysis showed that the most widely used antibiotic was Ceftriaxone with a 35.79 DDD/100 patient-days. The Gyssenss qualitative analysis showed that the category VI (incomplete patient's medical record data) was 3%, category IVa (antibiotic use is more effective) (2%), category IIIb (duration of antibiotic use is too short) (3%), category IIb (antibiotic use is not at the right interval) (3%).

STUDI PENGGUNAAN LOPINAVIR/RITONAVIR PADA PASIEN COVID-19 DERAJAT RINGAN-SEDANG DENGAN KOMORBID HIPERTENSI DAN DIABETES MELLITUS Didik Hasmono; Agriawan Sudirman; Muhammad Nashrullah; Ruddy Hartono; Mohammad Subhan
Jurnal Kesehatan Vol 16 No 1 (2023): JURNAL KESEHATAN
Publisher : Universitas Islam Negeri Alauddin Makassar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24252/kesehatan.v16i1.28711

Lopinavir/Ritonavir is proposed as one of the therapy for Covid-19 patients based on the ability to reduce viral load. Bhayangkara Hospital Surabaya is one of the hospitals with quite a lot of Covid-19 patients in Surabaya. The research aimed to determine the effectiveness, outcome, and evaluate side effects of Lopinavir/Ritonavir in mild to moderate Covid-19 patients with comorbid hypertension and diabetes mellitus at Bhayangkara Hospital Surabaya. This was an observational study that collected data retrospectively at Bhayangkara Hospital Surabaya. Patient data had to meet the requirements for inclusion criteria, which were patients treated with Lopinavir/Ritonavir for a Covid-19 mild to moderate with comorbid hypertension and diabetes mellitus. Data were obtained from 18 patient medical records and then processed descriptively. The results showed that 7 patients (39%) received therapy A with 11 days of treatment, 4 patients received therapy B (22%) with 12 days of treatment, 1 patient (11%) received therapy C with 18 days of treatment, and 6 patients (28%) on D therapy with 14 days of treatment. Patients experiencing effects of gastrointestinal disturbances such as nausea (22%), and diarrhea (11%). Lopinavir/Ritonavir in therapy A is the most effective when viewed from the length of treatment, which is 11 days. Therapy B, C, and D were considered effective as seen from the results of RT-PCR which showed negative results, namely 100%. Therapy D is the most effective chest X-ray repair, which is 50%. Side effects of Lopinavir/Ritonavir were gastrointestinal disturbances, namely nausea (22%), and diarrhea (11%), while hepatotoxicity was not found.

Studi Penggunaan Asam Traneksamat pada Pasien BPH dengan Operasi Transurethral Resection of The Prostate Irsan Fahmi Almuhtarihan; Aghnia Fuadatul Inayah; Didik Hasmono; Hendra Yadi
Jurnal Ilmiah Farmasi Farmasyifa Vol 6, No 2 (2023)
Publisher : Universitas Islam Bandung

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29313/jiff.v6i2.10547

Latar Belakang: Benign Prostatic Hyperplasia (BPH) merupakan kondisi ketika sel-sel prostat mengalami peningkatan pertumbuhan akibat sel stroma dan epitel yang terus mengalami proliferasi. BPH sering dialami oleh laki-laki usia >50 tahun dan biasanya disertai dengan gejala lower urinary tract symptoms (LUTS). Manajemen terapi pada BPH meliputi watchful waiting, terapi farmakologi dan tindakan pembedahan. Tindakan pembedahan termasuk penyelesaian gejala jangka panjang paling baik pada BPH. Transurethral Resection of The Prostate (TURP) adalah tindakan paling umum dilakukan dengan komplikasi utama adalah perdarahan. Asam traneksamat termasuk antifibrinolitik dan merupakan inhibitor kuat terhadap plasminogen dan urokinase. Obat ini bekerja dengan menghambat interaksi plasminogen dengan fibrin sehingga dapat mencegah fibrinolisis.Tujuan: Penelitian ini bertujuan untuk mengetahui pola penggunaan asam traneksamat pada pasien Benign Prostatic Hyperplasia di Rumah Sakit Umum Daerah Kabupaten Kediri.Metode: Penelitian dilakukan secara observasional dengan metode retrospektif pada pasien Benign Prostatic Hyperplasia di Rumah Sakit Umum Daerah Kabupaten Kediri periode Januari 2019 - November 2019.Hasil dan Kesimpulan: Pola penggunaan asam traneksamat hanya digunakan tunggal pada 40 pasien (100%) dengan regimentasi dosis paling banyak digunakan adalah (3x500mg) IV sebanyak 24 pasien (60%) dan lama terapi paling banyak diberikan sekitar 2-8 hari sebanyak 39 pasien (98%).

Studi Penggunaan Antihipertensi Golongan Angiotensin Reseptor Blocker (ARB) pada Pasien Chronic Kidney Disease (Penelitian dilakukan di RS Universitas Muhammadiyah Malang) Nurfausiah, Nurfausiah; Hasmono, Didik; Kusumaningtyas, Atika Putri; Syifa', Nailis
JFM (Jurnal Farmasi Malahayati) Vol 7, No 2 (2024)
Publisher : Jurnal Farmasi Malahayati (JFM)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33024/jfm.v7i2.15903

Hypertension and chronic kidney disease (CKD) are interrelated pathophysiological conditions, where sustained hypertension can lead the deterioration of renal function, and progressive deterioration of renal function can conversely result in poorer blood pressure (BP) control. Antihypertensives are given to CKD patients with the goal of lowering their blood pressure to < 140 mmHg and preventing harm to other organs. Angiotensin Receptor Blockers (ARB) are one of the first line of therapy used to reduce blood pressure in CKD patients. The research purpose was to determine the pattern of ARB regarding the type, dosage form, combination, and route of the group given to CKD patients at UMM’s General Hospital. Research was conducted in observational research with a descriptive nature and retrospective data collection on the health medical record of CKD with period January – Desember 2022. Results of the research showed that patients who met the inclusion criteria amounted to 25 patients using ARB antihypertensive therapy, the highest number of gender 52% male and 48% female, at the age of 46-55 years. The most common single use was Candesartan (1x16mg)po (5%) 2 patients, the most common combination II was Candesartan (1x16mg)po + Furosemide (3x40mg) iv 7 patients (18%), the most common combination III was Candesartan (1x16mg)po + Amlodipine (1x10mg)v + Furosemide (3x40mg)iv, the most common combination IV was Candesartan (1x16mg)po + Amlodipine (1x10mg)po + Clonidine (3x0.15mg)po + Furosemide (3x40mg)iv. There was a switch pattern as many as 13 samples (52%). Most patients met the blood pressure target at ≤ 140 mmHg.

Co-Authors Adinugraha Amarullah Aghnia Fuadatul Inayah Agriawan Sudirman Agriawan Sudirman Agus Sunarko Agus Sunarko Alfa Frista Arta Alfin Giovani Andilusia, Sindy Ardianty, Nonie Arina Dery Puspitasari Aryani, Dhita Aryani, Dhita Evi Astutik, Widi Atika Putri Kusumaningtyas Atmajani, Wanudya Awdisma, Wien Maryati Ayumuyas, Nur Palestin Ayumuyas, Nur Palestin Ayunda Nur Hidayatiningsih Bambang Sidharta Binti Muzayyanah Budi Suprapti Budiatin, Aniek Setiya Bura, Ursula Dua Klowe Chrysnanda Maryska Claudia Tiffany Dea Ayu Nabilah Dinda Monika Nusantara Ratri Dini Setiya Praja Dini Setiya Praja, Dini Setiya Donsu, Yosefien Christania Elisabeth Kasih Fadlilah, Umul Firandi, Adelia Ganesha T Trengginas Giovani, Alfin Hanum, Putri Safitri Hariyati, Fera Hariyati, Fera Hartono, Ruddy Hasbi As-Shiddiq Hendra Yadi Heni Pujiastuti Hidajah Rachmawati Hidajah Rachmawati Hidayah Karuniawati Hidayah, Ana Nurlaili IGD Ugrasena Ilfi Hanna, Az Zahra Insyirah Idris, Anissah Irianto, Jimmy Setiawan Irsan Fahmi Almuhtarihan Irsan Fahmi Almuhtarihan Ismawati Isparnadi, Erwien Issaura, Issaura Jenggo Suwarko Joko Semedi Junaidi Khotib Khairil Armal Kuntaman Kuntaman Kusumaningtyas, Atika Putri Lilik Yusetyani Lilik Yusetyani Machin, Abdulloh Mahardian Rahmadi Mareta Rindang Andarsari Maria Angelia Yoshida Meiliana, Made Laksmi Meo, Maria Lettisia Mia Melinda Mohammad Saiful Islam Mohammad Subhan Mohammad Subhan Mohammad Subhan Mohammad Subkhan Muhammad Nashrullah Muktamiroh Muktamiroh Nadriatul Utami Nailis Syifa Ni Made Eravikania Putri Darmawan Nun Zairina, Nun Nur Hadiyanti Nuraida Wisudani Nurfausiah, Nurfausiah Nurmainah Nurmainah Nurul Ma'rifah Paulus Sugianto Pharmasinta Putri Hapsari Pramadani, Yana Puri Safitri Hanum Puspitasari, Diny Putri Nurhidayah, Eka Ramdani, Dewi Retna Dwi Puspitarini Rino Wahyudi, Rino Risa Septinia Rizki Lisya Nugraha Roni Subagyo RR. Ella Evrita Hestiandari Ruddy Hartono Ruddy Hartono Ruddy Hartono Ruddy Hartono Ruhaya Fitrina, Ruhaya Samirah Samirah Sandra J. Parambang Sandra, Pipit Semedi, Joko Sendi Lia Yunita Setiawan, Landia Siti Surdijati Siti Surdijati, Siti Sofiati Diah Baisuni Suharjono Suharjono, Suharjono Sumarno Sumarno Syifa', Nailis Syifa, Nailis' Tanasy, Marledy Taufiqur Rahman, Taufiqur Thayyib, Muqoddar Tista Ayu Fortuna Ulfa Syafli Nosa Usman Hadi Utami, Nadriatul Wardhani, Firdha Aprillia Wardhani, Hety Setya Widi Astutik Widi Astutik Wien Maryati Awdisma Wiranata, I Made Worotikan, Natania Imanuella Yosefien Christania Donsu Yudi Agung Wibisono Yudistira Nurrizky Grahitaning Putra Rohmaana Yulistiani Yulistiani Yulistiani, . Yuni, Santi Eka Yuni, Santi Eka

Title

Found 72 Documents
Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title Search

Found 72 Documents Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title

Found 72 Documents
Search